Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.8 CAD -3.74% Market Closed
Market Cap: 146.9m CAD
Have any thoughts about
Cardiol Therapeutics Inc?
Write Note

Cardiol Therapeutics Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cardiol Therapeutics Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Total Current Assets
CA$17.3m
CAGR 3-Years
-18%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Total Current Assets
CA$391.7m
CAGR 3-Years
-46%
CAGR 5-Years
-36%
CAGR 10-Years
41%
Sundial Growers Inc
NASDAQ:SNDL
Total Current Assets
CA$406.9m
CAGR 3-Years
51%
CAGR 5-Years
80%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Total Current Assets
$959.2m
CAGR 3-Years
-5%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Total Current Assets
$299.4m
CAGR 3-Years
27%
CAGR 5-Years
153%
CAGR 10-Years
99%
C
Curaleaf Holdings Inc
CNSX:CURA
Total Current Assets
$483.8m
CAGR 3-Years
9%
CAGR 5-Years
446%
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
146.9m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
0.73 CAD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Total Current Assets?
Total Current Assets
17.3m CAD

Based on the financial report for Sep 30, 2024, Cardiol Therapeutics Inc's Total Current Assets amounts to 17.3m CAD.

What is Cardiol Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
0%

Over the last year, the Total Current Assets growth was -59%. The average annual Total Current Assets growth rates for Cardiol Therapeutics Inc have been -18% over the past three years .

Back to Top